At the news
? BULLISHIMPACT 5/10 8-K filed Nov 9, 2026 at 08:52 ET
Axogen hosted an investor event announcing its decision to launch into the prostate nerve reconstruction market using its Avance nerve allograft. The presentation cited a $754 million total addressable market and clinical data showing improved erectile function recovery versus historical controls. No financial results or guidance were provided.
- Axogen announced a decision to launch into the prostate nerve reconstruction market
- Total addressable market estimated at $754 million with a weighted ASP of ~$7,000 per procedure
- Clinical data from 117 patients with at least 6 months follow-up showed ~80% had better than expected erectile function and >95% return of continence
- Over 220 patients have been reconstructed with Avance nerve allograft in prostate procedures
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access